OncoK9 – Cancer Monitoring White Paper | PetDx®

OncoK9 – Cancer Monitoring White Paper

Evaluation of OncoK9® for Detection of Residual Disease and Cancer Recurrence in Dogs



Key Takeaways

  • Over 95% of samples with a Cancer Signal Detected OncoK9 result had presence of clinical disease at the same visit or at a future visit, demonstrating detection of molecular recurrence.
  • Following excisional surgery, in the absence of clinical residual disease at the first post-operative visit, patients with a Cancer Signal Detected OncoK9 test result at that visit (indicative of molecular residual disease) were found to be twice as likely to have clinical recurrence within 6 months compared to patients with a Cancer Signal Not Detected result.
  • In patients with a complete response (CR) following therapy, but with subsequent clinical recurrence during a 12-month observation period, 70% had cancer signal detected by the OncoK9 test prior to or concomitant with clinical recurrence; molecular recurrence was detected prior to clinical recurrence in 37% of those cases, with a median lead time of more than 2 months.
  • Next-generation sequencing based liquid biopsy is a new, non-invasive tool that has the potential to improve cancer monitoring for dogs in the post-diagnosis setting. Patients with no clinical evidence of disease but with molecular residual disease or molecular recurrence detected by the OncoK9 test may benefit from closer clinical evaluation and monitoring.

Join the Revolution in Early Cancer Detection for Dogs

If you are ready to add the OncoK9 multi-cancer early detection test to your veterinary practice, we would love to hear from you.